Trial site
Institute of Hematology and Hospital of Blood Disease
Tianjin, 300020, ChinaNot linked to an institution yet
- 10running trials
- 4closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Active, not recruiting7 trials
- Completed3 trials
- Recruiting3 trials
- Terminated1 trial
- Lead sponsor
- BeOne Medicines7 trials
- BeiGene4 trials
- Hoffmann-La Roche2 trials
- Daiichi Sankyo1 trial
Running trials
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037· Phase 2· BeOne Medicines· Source
Active, not recruiting
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994· Phase 2· BeiGene· Source
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731· Phase 1/2· BeOne Medicines· Source
Contact: BeOne Medicines
Active, not recruiting
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
NCT04654468· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333· Phase 3· BeiGene· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error